Bioanalytical Systems, Inc. (BASI) Insider Purchases $11,640.00 in Stock

Bioanalytical Systems, Inc. (NASDAQ:BASI) insider Robert Jr. Leasure bought 6,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was acquired at an average price of $1.94 per share, for a total transaction of $11,640.00. Following the completion of the transaction, the insider now owns 99,615 shares in the company, valued at $193,253.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Robert Jr. Leasure also recently made the following trade(s):

  • On Friday, March 8th, Robert Jr. Leasure bought 4,000 shares of Bioanalytical Systems stock. The stock was acquired at an average price of $1.77 per share, for a total transaction of $7,080.00.
  • On Thursday, February 28th, Robert Jr. Leasure bought 8,900 shares of Bioanalytical Systems stock. The stock was acquired at an average price of $1.51 per share, for a total transaction of $13,439.00.

BASI traded down $0.04 during trading hours on Friday, hitting $1.90. The company’s stock had a trading volume of 13,815 shares, compared to its average volume of 20,368. Bioanalytical Systems, Inc. has a fifty-two week low of $1.18 and a fifty-two week high of $2.59. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.65 and a quick ratio of 0.56. The stock has a market cap of $19.45 million, a P/E ratio of 63.00 and a beta of 0.90.

Bioanalytical Systems (NASDAQ:BASI) last posted its earnings results on Thursday, February 14th. The company reported ($0.01) EPS for the quarter. Bioanalytical Systems had a negative net margin of 1.03% and a positive return on equity of 3.28%. The business had revenue of $8.63 million during the quarter.

An institutional investor recently raised its position in Bioanalytical Systems stock. Monument Capital Management boosted its holdings in Bioanalytical Systems, Inc. (NASDAQ:BASI) by 220.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 172,000 shares of the company’s stock after acquiring an additional 118,300 shares during the quarter. Monument Capital Management owned 1.68% of Bioanalytical Systems worth $218,000 at the end of the most recent quarter. 7.63% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at

About Bioanalytical Systems

Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products.

Read More: What is Cost of Capital?

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with's FREE daily email newsletter.